Biology:Interleukin 29
Generic protein structure example |
Interleukin-29 (IL-29) is a cytokine and it belongs to type III interferons group, also termed interferons λ (IFN-λ). IL-29 (alternative name IFNλ1) plays an important role in the immune response against pathogenes and especially against viruses by mechanisms similar to type I interferons, but targeting primarily cells of epithelial origin and hepatocytes.[1][2]
IL-29 is encoded by the IFNL1 gene located on chromosome 19 in humans.[1][3] It is a pseudogene in mice meaning the IL-29 protein is not produced in them.[1]
Structure
IL-29 is, with the rest of IFN-λ, structurally related to the IL-10 family, but its primary amino acid sequence (and also function) is more similar to type I interferons.[1] It binds to a heterodimeric receptor composed of one subunit IFNL1R specific for IFN-λ and a second subunit IL10RB shared among the IL-10 family cytokines.[1]
Function
Effects on immune response to pathogens
IL-29 exhibits antiviral effects by inducing similar signaling pathways as type I interferons.[1] IL-29 receptor signals through JAK-STAT pathways leading to activated expression of interferon-stimulated genes and production of antiviral proteins.[4] Further consequences of IL-29 signalization comprise the upregulated expression of MHC class I molecules,[1] or enhanced expression of the costimulatory molecules and chemokine receptors on pDC, which are the main producers of IFN-α.[4]
IL-29 expression is dominant in virus-infected epithelial cells of the respiratory, gastrointestinal and urogenital tracts, also in other mucosal tissues and skin. Hepatocytes infected by HCV or HBV viruses stimulate the immune response by producing IL-29 (IFN-λ in general) rather than type I interferons.[1][2] It is also produced by maturing macrophages, dendritic cells or mastocytes.[2]
It plays a role in defense against pathogens apart from viruses.[1] It affects the function of both innate and adaptive immune system. Besides described antiviral effects, IL-29 modulates cytokine production of other cells, for example, it increases secretion of IL-6, IL-8 and IL-10 by monocytes and macrophages, enhances the responsiveness of macrophages to IFN-γ by increased expression of IFNGR1, stimulates T cell polarization towards Th1 phenotype and also B cell response to IL-29 was reported.[4]
Antitumor immunity
The impact of IL-29 on cancer cells is complicated depending on cancer cell type. It shows protective tumor inhibiting effects in many cases such as skin, lung, colorectal or hepatocellular cancer, but shows tumor promoting effects on multiple myeloma cells.[2] IFN-λ have potential as cancer therapy, with effects on more restricted cell types and fewer side-effects than type I interferons.[1][2]
Autoimmune diseases
Abnormal expression of IL-29 could be involved in the pathogenesis of the autoimmune diseases by enhancing the production of inflammatory cytokines, chemokines, and other autoimmune‐related components. High levels of IL-29 in serum or disease-specific tissue was observed in patients with rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Sjögren's syndrome, psoriasis, atopic dermatitis, Hashimoto's thyroiditis, systemic sclerosis and uveitis.[4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "Interferon-λ: Immune Functions at Barrier Surfaces and Beyond". Immunity 43 (1): 15–28. July 2015. doi:10.1016/j.immuni.2015.07.001. PMID 26200010.
- ↑ 2.0 2.1 2.2 2.3 2.4 "The role of IL-29 in immunity and cancer". Critical Reviews in Oncology/Hematology 106: 91–8. October 2016. doi:10.1016/j.critrevonc.2016.08.002. PMID 27637354.
- ↑ "Entrez Gene: interleukin 29 (interferon". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=282618.
- ↑ 4.0 4.1 4.2 4.3 "Insights into IL-29: Emerging role in inflammatory autoimmune diseases". Journal of Cellular and Molecular Medicine 23 (12): 7926–7932. December 2019. doi:10.1111/jcmm.14697. PMID 31578802.
Further reading
- "Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication". The Journal of Biological Chemistry 283 (44): 30079–89. October 2008. doi:10.1074/jbc.M804296200. PMID 18757365.
- "Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells". Acta Pharmacologica Sinica 27 (4): 453–9. April 2006. doi:10.1111/j.1745-7254.2006.00292.x. PMID 16539846.
- "Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29)". Journal of Leukocyte Biology 86 (6): 1359–63. December 2009. doi:10.1189/jlb.0509347. PMID 19759281.
- "IL-28 and IL-29: newcomers to the interferon family". Biochimie 89 (6–7): 729–34. 2007. doi:10.1016/j.biochi.2007.01.008. PMID 17367910.
- "Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages". Journal of Virology 83 (8): 3834–42. April 2009. doi:10.1128/JVI.01773-08. PMID 19193806.
- "Purification, crystallization and preliminary crystallographic studies of the complex of interferon-lambda1 with its receptor". Acta Crystallographica Section F 66 (Pt 1): 61–3. January 2010. doi:10.1107/S1744309109048817. PMID 20057073.
- "Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection". Journal of Virology 84 (18): 9140–8. September 2010. doi:10.1128/JVI.00717-10. PMID 20592090.
- "IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression". American Journal of Physiology. Gastrointestinal and Liver Physiology 289 (5): G960–8. November 2005. doi:10.1152/ajpgi.00126.2005. PMID 16051921.
- "Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner". Genes and Immunity 8 (2): 177–80. March 2007. doi:10.1038/sj.gene.6364372. PMID 17252004.
- "Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses". Journal of Leukocyte Biology 86 (1): 23–32. July 2009. doi:10.1189/jlb.1208761. PMID 19304895.
- "Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29)". Genes and Immunity 8 (1): 13–20. January 2007. doi:10.1038/sj.gene.6364348. PMID 17082759.
- "Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection". Journal of Immunology 182 (3): 1296–304. February 2009. doi:10.4049/jimmunol.182.3.1296. PMID 19155475.
- "Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma". Cancer Research 66 (8): 4468–77. April 2006. doi:10.1158/0008-5472.CAN-05-3653. PMID 16618774.
- "Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells". Journal of Virology 79 (15): 9608–17. August 2005. doi:10.1128/JVI.79.15.9608-9617.2005. PMID 16014923.
- "IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity". Cancer Biology & Therapy 7 (7): 1109–15. July 2008. doi:10.4161/cbt.7.7.6192. PMID 18698163.
- "Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells". Blood 107 (11): 4417–23. June 2006. doi:10.1182/blood-2005-10-4129. PMID 16478884.
- "Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes". Journal of Leukocyte Biology 83 (5): 1181–93. May 2008. doi:10.1189/jlb.0807525. PMID 18281438.
- "A role for IFN-lambda1 in multiple myeloma B cell growth". Leukemia 22 (12): 2240–6. December 2008. doi:10.1038/leu.2008.263. PMID 18830264.
- "Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines". Genes and Immunity 10 (8): 702–14. December 2009. doi:10.1038/gene.2009.72. PMID 19798076.
- "Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study". Gastroenterology 138 (4): 1338–45, 1345.e1–7. April 2010. doi:10.1053/j.gastro.2009.12.056. PMID 20060832.
Original source: https://en.wikipedia.org/wiki/Interleukin 29.
Read more |